

Mufaddal K Mamawala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4866615/publications.pdf>

Version: 2024-02-01

32
papers

1,262
citations

516710

16
h-index

642732

23
g-index

32
all docs

32
docs citations

32
times ranked

1978
citing authors

#	ARTICLE	IF	CITATIONS
1	Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3379-3385.	1.6	454
2	Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2019, 75, 743-749.	1.9	138
3	Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. <i>European Urology</i> , 2020, 77, 675-682.	1.9	137
4	The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. <i>European Urology</i> , 2017, 71, 174-180.	1.9	75
5	Prostate Health Index density improves detection of clinically significant prostate cancer. <i>BJU International</i> , 2017, 120, 793-798.	2.5	69
6	A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. <i>Prostate</i> , 2018, 78, 607-615.	2.3	57
7	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. <i>European Urology</i> , 2016, 69, 576-581.	1.9	42
8	Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer. <i>BJU International</i> , 2019, 124, 268-274.	2.5	36
9	Conditional Probability of Reclassification in an Active Surveillance Program for Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 1950-1955.	0.4	32
10	Risk prediction tool for grade reclassification in men with favourable-risk prostate cancer on active surveillance. <i>BJU International</i> , 2017, 120, 25-31.	2.5	29
11	Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance. <i>BJU International</i> , 2020, 126, 373-378.	2.5	25
12	A Bayesian Hierarchical Model for Prediction of Latent Health States from Multiple Data Sources with Application to Active Surveillance of Prostate Cancer. <i>Biometrics</i> , 2017, 73, 625-634.	1.4	23
13	Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. <i>Journal of Urology</i> , 2021, 205, 1069-1074.	0.4	21
14	Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer. <i>European Urology</i> , 2017, 72, 135-141.	1.9	20
15	Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance. <i>Journal of Urology</i> , 2019, 201, 98-105.	0.4	20
16	Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. <i>BJU International</i> , 2020, 125, 861-866.	2.5	19
17	PTEN status assessment in the Johns Hopkins active surveillance cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 176-181.	3.9	13
18	Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies. <i>Cancer</i> , 2018, 124, 698-705.	4.1	12

#	ARTICLE	IF	CITATIONS
19	Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance. Journal of Urology, 2018, 199, 954-960.	0.4	11
20	Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients. Prostate, 2021, 81, 703-709.	2.3	11
21	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
22	Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease. Journal of Urology, 2017, 198, 608-613.	0.4	6
23	Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Urology, 2020, 138, 84-90.	1.0	2
24	MP9-02 OLDER AGE PREDICTS GLEASON SCORE UPGRADING DURING LONG-TERM MONITORING ON ACTIVE SURVEILLANCE. Journal of Urology, 2015, 193, .	0.4	0
25	MP42-04 ACTIVE SURVEILLANCE: WHEN CAN PATIENTS STOP WORRYING?. Journal of Urology, 2015, 193, .	0.4	0
26	MP15-08 IS PSA DENSITY OR PSA (OR NEITHER) USEFUL TO PREDICT BIOPSY RECLASSIFICATION IN ACTIVE SURVEILLANCE PATIENTS?. Journal of Urology, 2016, 195, .	0.4	0
27	MP15-09 BASELINE AND LONGITUDINAL PCA3 PREDICT MORE EXTENSIVE CANCER IN AN ACTIVE SURVEILLANCE POPULATION. Journal of Urology, 2016, 195, .	0.4	0
28	Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sondi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576â€“81. European Urology, 2017, 71, e13.	1.9	0
29	Can frequency of prostate biopsy on active surveillance be reduced without significantly increasing risk?. Journal of Clinical Oncology, 2017, 35, e546-e546.	1.6	0
30	Comparison of biochemical recurrence-free survival after radical prostatectomy among men in active surveillance following grade reclassification and men newly diagnosed with similar grade disease.. Journal of Clinical Oncology, 2017, 35, 117-117.	1.6	0
31	Comparison of biochemical recurrence free survival after radical prostatectomy triggered by grade reclassification on active surveillance, and men newly diagnosed with similar grade disease.. Journal of Clinical Oncology, 2017, 35, 5047-5047.	1.6	0
32	106 Cumulative Cancer Location Incidence and Cancer Progression in an Active Surveillance Cohort. Journal of Clinical and Translational Science, 2022, 6, 2-2.	0.6	0